#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neuroendocrine cell hyperplasia of infancy Oesophageal squamous cell carcinoma stage II Facioscapulohumeral muscular dystrophy Small cell lung cancer extensive stage Pleural mesothelioma Endometrial adenocarcinoma Alveolar proteinosis Arteriovenous malformation Oesophageal carcinoma Urea cycle disorder Metastatic malignant melanoma Progressive supranuclear palsy Monogenic diabetes Pneumonia Primary mediastinal large B-cell lymphoma More trials…

    Learn about Rare Diseases

    Mastocytosis – Treatment Progressive multifocal leukoencephalopathy – Trials in Disease Extranodal marginal zone B-cell lymphoma (MALT type) – Trials in Disease Stevens-Johnson syndrome – Diagnostics Glomerulonephritis membranoproliferative X-linked lymphoproliferative syndrome Proteus syndrome – Treatment Haemophilia – Basic Information Rosai-Dorfman syndrome – Basic Information Gaucher’s disease type I – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    AMO959 Lidocaine Glycerol Phenylbutyrate Bnt314 Ethambutol Hydrochloride Benralizumab Amantadine Hydrochloride Paracetamol Gad20-209-Fsp-A3 Carbetocin Cefixime Trihydrate Valemetostat Tosilate Calcium Oxybate GRNA1599 Luspatercept Vo659 IHMA-2121908-1 Naltrexone Hydrochloride Medi0618 Dantrolene Sodium More therapies…

    Learn about Your Condition

    Adrenogenital syndrome Small fibre neuropathy BK virus infection Head and neck cancer stage III Peripheral artery angioplasty Henoch-Schonlein purpura Tricuspid valve disease Proteus syndrome Mitral valve disease Bronchiolitis Infantile apnoea Neuroblastoma Bone marrow failure Craniopharyngioma Torticollis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hereditary angioedema

  • Study of Deucrictibant Extended-Release Tablets for Prevention of Hereditary Angioedema Attacks in Adults and Adolescents

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hereditary angioedema
    Investigated Drugs:
    • Icatibant
    • Deucrictibant
    Bulgaria France Germany Hungary Ireland Italy +4

  • Study on the Safety and Effects of Berotralstat for Children Aged 2 to 12 with Hereditary Angioedema (HAE)

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hereditary angioedema
    Investigated Drugs:
    • Berotralstat
    Austria France Germany Italy Poland Spain

  • Study on the Safety of Donidalorsen for Patients with Hereditary Angioedema

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Hereditary angioedema
    Investigated Drugs:
    • Donidalorsen
    The Netherlands

  • Study on the Long-Term Safety of STAR-0215 for Adults with Hereditary Angioedema

    Not recruiting

    2 1 1
    Investigated Drugs:
    • NAVENIBART
    Bulgaria Czechia Germany Poland

  • Study on Oral PHA-022121 for Preventing Angioedema Attacks in Patients with Hereditary Angioedema

    Not recruiting

    2 1
    Investigated Diseases:
    • Hereditary angioedema with C1 esterase inhibitor deficiency
    • Hereditary angioedema
    Investigated Drugs:
    • (S)-N-(1-Deutero-1-(3-Chloro-5-Fluoro-2-((2-Methyl-4-(1-Methyl-1H-1,2,4-Triazol-5-Yl)Quinolin-8-Yloxy)Methyl)Phenyl)Ethyl)-2-(Difluoromethoxy)Acetamide
    Austria Bulgaria Germany Ireland Italy Poland

  • Study on Long-Term Safety of Donidalorsen for Patients with Hereditary Angioedema

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Donidalorsen
    Belgium Bulgaria France Germany Italy The Netherlands +2
Previous Page
1 2 3 4
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!